Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study

Saved in:
Bibliographic Details
Published in:PloS one 2024-01, Vol.19 (11)
Main Authors: Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1932-6203